ANIMAL MODELS OF HIV INFECTION
many questions concerned with HIV biology were first learned in cultured cell
lines infected with HIV or SIV, it became obvious that these cultured lines did
not truly mimic the wild-type infections seen in animal models. A number of
small rodent models, such as the SCID mouse, were developed and were helpful
but somewhat artificial and did not really mimic human disease.
a significant obstacle in HIV vaccine research has been the difficulty in
developing an appropriate animal model with many of the features of human HIV
infection. The only animals susceptible to experimental infections with HIV are
chimpanzees, Pantroglodytes, and
pigtail macaques, Macaca nemestrina.
These ani-mals maintain low levels of persistent virus but do not develop
clinical manifesta-tions of AIDS. In contrast, Asian monkeys, especially rhesus
monkeys from India, are highly susceptible to SIVmac infec-tion and
progressively develop an immu-nodeficiency syndrome that is similar to human
AIDS. Plasma viral levels during acute and chronic SIVmac251 infection in these
animals parallel those observed in humans, with some animals containing virus
spontaneously and progressing to disease slowly as in HIV-1 infected human
long-term nonprogressors. In con-trast, others maintain high viral loads and
behave like human rapid progresses. As in HIV-1 infected humans, the cellular
immune response to SIVmac during acute and chronic disease differs
significantly, and evidence of immune escape has been well documented. This is
particularly true of the mucosal immune system, especially the many CD4+
CCR-5+ T cells in the gut-associated lymphoid tissue, the major site of viral
replication and of CD4+ T-cell depletion in SIV-infected macaques.
This also mimics the human disease and thus the SIV macaque model is currently
con-sidered the most appropriate animal model for studies on potential
protective immune responses against HIV.
animal model of HIV vaccine research is based on the use of SIV/HIV hybrid
viruses that were engineered to carry the env
gene from HIV into the con-tent of the SIV genome. These viruses do replicate
in rhesus macaques and after serial macaque passages do lead to the emergence
of highly pathogenic SHIV variants that can wipe out circulating CD4+
T cells within a few weeks and lead to a lethal immunodeficiency syndrome
within a year of infection.
the problem has been whether these variants, like SHIV 89.6P, are relevant to
HIV infections. For exam-ple, they exhibit an “X4” cellular tropism and are
therefore easier to contain by vac-cine-induced immune response than “R5”
viruses such as SIV. If we could obtain SHIV strains with R5 tropism, this
might be a better model to study.
problem with the monkey models is that experiments to evaluate vac-cine efficacy
requires challenging the vac-cinated animals with high doses of virus to get
100 percent infection, that is, 103 – 105 TCID50
equivalent to 5 × 107 SIV RNA cop-ies/ml. This is in marked contrast
to natu-ral exposure to HIV in humans wherein the doses of 103 HIV
RNA copies/ml of semi-nal plasma have been reported. However, these results are
quite different in mucosal challenge, wherein reported low doses (10–30 TCID50)
with SIV results in the same viral and immunological kinetics of infection as
high-dose challenges. Thus, this new type of mucosal challenge might change the
results of preclinical vaccine efficacy studies in the future.